Oral options and compounded GLP-1 products
“Oral GLP-1” and “compounded GLP-1” are the two phrases most likely to detach a product from its label. Oral can mean an FDA-approved tablet with a specific indication. Compounded can mean a preparation FDA has not approved as a finished drug. They are not synonyms, and neither one is a mild version of a weekly pen. This entry separates the tablets that have labels from the products FDA has warned about. How online offers use these words is explained for readers on what “GLP-1 online” means. Manufacturer savings offers, which generally apply to approved products rather than to compounded vials, are outlined on a savings sheet.
Wegovy tablets
Wegovy tablets are semaglutide indicated, with a reduced-calorie diet and increased physical activity, to reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction in adults with obesity or with overweight plus a weight-related comorbid condition. They are not labeled in the dosing section reviewed here as the pediatric weight-reduction product. The injection carries the adolescent obesity indication.
The tablet schedule is 1.5 mg once daily on days 1 through 30, 4 mg on days 31 through 60, 9 mg on days 61 through 90, and 25 mg from day 91 onward. Maintenance for those adult uses is 25 mg once daily. If that dose is not tolerated, the label says to consider a switch to Wegovy injection 1.7 mg weekly, under the switching subsection, not to cut tablets. Tablets are swallowed whole, one a day, in the morning, on an empty stomach, with no more than 4 ounces of water. No other liquids. Wait at least 30 minutes before food, drink, or other oral medicines. A missed tablet is skipped. Taking the tablet with coffee, or with a full glass of juice, is a different administration than the one the label studied.
The label allows defined switches between Wegovy injection 2.4 mg and Wegovy tablets 25 mg. It does not allow using both together, and it does not allow combining either one with Ozempic, Rybelsus, or another GLP-1 receptor agonist.
Rybelsus and Ozempic tablets
Rybelsus and the Ozempic tablets that share its DailyMed record are indicated for glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise, and to reduce major adverse cardiovascular events in adults with type 2 diabetes who are at high risk. That is a diabetes label. It is not the Wegovy weight-management indication, even though the molecule is semaglutide and weight change can occur.
On the record reviewed, Rybelsus starts at 3 mg once daily for 30 days. The label says this starting dose is not effective for glycemic control. The dose increases to 7 mg daily. If additional glycemic control is needed from day 61 onward, the dose may increase to 14 mg. If it is not needed, the dose stays at 7 mg. Administration matches the empty-stomach, up-to-4-ounces-of-water, 30-minute-wait pattern. A missed dose is skipped. The record states that Rybelsus and Ozempic tablets are not substitutable on a milligram-per-milligram basis, and it warns against improvising a 14 mg dose by doubling tablets if the label says not to. Read that administration section rather than scaling by arithmetic. A 14 mg Rybelsus tablet is not half of a 25 mg Wegovy tablet in any labeled sense. Different formulations, different indications, different escalations.
Older Rybelsus labels described two formulations, sometimes called R1 and R2, that were not substitutable. If a pharmacy dispenses a strength such as 1.5 mg, 4 mg, or 9 mg under the Rybelsus name, do not assume it matches either the 3/7/14 ladder or the Wegovy 1.5/4/9/25 ladder. Match the name on the bottle to the dosing subsection for that formulation. This is a common point of confusion precisely because some of those milligrams coincide.
What “compounded” means here
FDA’s page on unapproved GLP-1 drugs used for weight loss says the agency knows patients and clinicians may seek unapproved versions of semaglutide and tirzepatide. It says unapproved versions do not undergo FDA review for safety, effectiveness, and quality before marketing. It says a compounded drug might be appropriate if a patient’s medical need cannot be met by an approved drug, or if the approved drug is not commercially available, and that compounded drugs are still not FDA-approved. It tells patients to obtain a prescription and fill it at a state-licensed pharmacy.
The same page describes fraudulent compounded products whose labels name pharmacies that do not exist or that did not make the product, and at least one adverse-event report tied to a product labeled as compounded tirzepatide from a pharmacy that had not compounded it. It describes dosing errors with compounded injectable semaglutide, some requiring hospitalization, from patients measuring the wrong volume and from clinicians miscalculating. A separate FDA compounding alert repeats that overdose pattern and states that compounded drugs pose a higher risk than approved drugs because they lack FDA premarket review.
FDA has also said it has received reports tied to compounded semaglutide or tirzepatide prescribed in doses beyond the approved label, including larger single doses, more frequent dosing, or faster titration, with events such as nausea, vomiting, diarrhea, abdominal pain, and constipation, some of them serious. Salt forms of semaglutide have been sold by some compounders. The agency has indicated those salts are not the same as the base form in the approved drugs. The page also states that retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition. Selling them as a compounded “GLP-1” is not a gray-area generic.
In 2025 and 2026 FDA communications, the agency said it intends to act against GLP-1 ingredients used in non-approved compounded drugs mass-marketed as similar alternatives to approved drugs, that compounded drugs must not be promoted as generics or as the same as the approved drug, and that it has warned telehealth companies over claims that obscure whether the seller even compounded the product. FDA also described a “green list” import alert aimed at GLP-1 active ingredients from foreign facilities that have not been evaluated as meeting applicable standards. Those actions are enforcement context. They do not convert a particular pharmacy’s vial into an approved product, and they do not mean every compounded prescription is illegal. They mean the marketing claim “it’s the same as Wegovy” is one FDA has said companies may not make.
Questions that keep the categories straight
Ask the seller to answer in words a pharmacist would recognize.
- Is the container an FDA-approved Wegovy tablet, an FDA-approved Rybelsus or Ozempic tablet, or a compounded preparation?
- If it is approved, which DailyMed label’s dosing table is being followed, and is the indication weight management, diabetes, or something else?
- If it is compounded, what is the state-licensed pharmacy, what is the concentration in milligrams per milliliter, and what volume is one dose?
- Does the dose or the titration go beyond the approved label for the approved drug it is being compared with?
- Is anyone calling it a generic? FDA has said compounded drugs are not generics.
An online offer can be a legitimate evaluation that results in an approved tablet. It can also be a subscription for a compounded liquid with a measuring syringe. The price difference does not tell you which one you have. The label difference does. Semaglutide holds the approved schedules. Which medicines holds the indication map. If a product is not on that map, this reference has not cleared it, and a chatbot’s reassurance is not a review.
Label and trial list
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
- https://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients
- https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- https://glp1.here/guides/what-glp-1-online-means
- https://glp1rx.org/steps/savings-offers